Evidence map›Paper›PMID 23846335›Full record

ArticleDer Nervenarzt2013

[Inhalative loxapine: old tried and trusted medication with new indications].

G Juckel

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Nervenarzt, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. [Acute agitation conditions].Der Nervenarzt · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

G JuckelKlinik für Psychiatrie, Psychotherapie und Präventivmedizin, LWL-Universitätsklinikum, Ruhr-Universität Bochum, Deutschland. Georg.juckel@wkp-lwl.org

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhalative loxapine which will come onto the market shortly, is an important new alternative medication for the treatment of agitation, restlessness and tension in patients with schizophrenia and bipolar disorders. The possibility of inhaled administration provides an advantage for patients and staff in certain acute situations. In patients with obstructive lung diseases there is a danger concerning bronchospasms. The resulting safety regulations limit the easy and broad usage of inhaled loxapine slightly but these can be easily realized within hospitals. In view of the rapid onset antiagitation effect and the easy handling of inhaled loxapine, this might be a rather minor problem.

Indexed as

Evidence-Based MedicineAdministration, InhalationAntipsychotic AgentsBipolar DisorderHumansLoxapinePsychomotor AgitationSchizophreniaStress, PsychologicalAntipsychotic AgentsLoxapine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.